abstract
- Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.
Overview
authors
publication date
- December 8, 2020
published in
- Blood advances Journal
Research
keywords
- Glycine
- Leukemia, Myeloid, Acute
- Pyridines
Identity
PubMed Central ID
- PMC7724900
Scopus Document Identifier
- 85098065877
Digital Object Identifier (DOI)
- 10.1101/2020.02.07.938860v1
PubMed ID
- 33284943
Additional Document Info
has global citation frequency
volume
- 4
issue
- 23